Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.
about
Clinical use of the co-formulation of insulin degludec and insulin aspart.A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study.Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.Trials of new anti-diabetes agents.
P2860
Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of once-da ...... omized, treat-to-target study.
@en
Efficacy and safety of once-da ...... omized, treat-to-target study.
@nl
type
label
Efficacy and safety of once-da ...... omized, treat-to-target study.
@en
Efficacy and safety of once-da ...... omized, treat-to-target study.
@nl
prefLabel
Efficacy and safety of once-da ...... omized, treat-to-target study.
@en
Efficacy and safety of once-da ...... omized, treat-to-target study.
@nl
P2093
P2860
P356
P1433
P1476
Efficacy and safety of once-da ...... omized, treat-to-target study.
@en
P2093
P2860
P304
P356
10.1111/DME.13125
P577
2016-03-30T00:00:00Z